- Joined
- Mar 15, 2023
- Messages
- 1,636
I'm sure that many have noticed how Primo performed almost unexpectedly well even at low doses in that study, but...Human beings express 4 different isozymes that can catalyze 3α-reduction. All are able to catalyze 3α-reduction, and differ in their tissues distribution and substrate specificity. This is in sharp contrast with what can be observed in the rat, that expresses only a single enzyme that’s capable of 3α-reduction. Because of the presence of multiple enzymes being able to catalyze 3α-reduction, as well as the single one in rats not being identical to any of the 4 isozymes round in men, a certain caution should be taken when extrapolating resulta from rats to humans in this scenario. This is to say that in men primo may follow a similar fate of that observed with DHT (deactvation in muscle tissue before it reaches the AR) albeit to a lesser extent.